open access

Vol 26, No 1 (2019)
Published online: 2019-03-14
Get Citation

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

Łukasz Kołtowski, Jacek Legutko, Krzysztof J. Filipiak, Artur Dziewierz, Stanisław Bartuś, Paweł Buszman, Piotr Buszman, Dariusz Ciećwierz, Maciej Dąbrowski, Sławomir Dobrzycki, Robert Gil, Jarosław Gorący, Marek Grygier, Miłosz Jaguszewski, Janusz Kochman, Jacek Kubica, Wiktor Kuliczkowki, Piotr Lodziński, Andrzej Ochała, Krzysztof Reczuch, Adam Witkowski, Wojciech Wojakowski, Jarosław Wójcik, Dariusz Dudek
DOI: 10.5603/CJ.2019.0029
Pubmed: 30882184
Cardiol J 2019;26(1):1-7.

open access

Vol 26, No 1 (2019)
Published online: 2019-03-14


Not available


Not available
Get Citation
About this article

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society


Cardiology Journal


Vol 26, No 1 (2019)



Published online






Bibliographic record

Cardiol J 2019;26(1):1-7.


Łukasz Kołtowski
Jacek Legutko
Krzysztof J. Filipiak
Artur Dziewierz
Stanisław Bartuś
Paweł Buszman
Piotr Buszman
Dariusz Ciećwierz
Maciej Dąbrowski
Sławomir Dobrzycki
Robert Gil
Jarosław Gorący
Marek Grygier
Miłosz Jaguszewski
Janusz Kochman
Jacek Kubica
Wiktor Kuliczkowki
Piotr Lodziński
Andrzej Ochała
Krzysztof Reczuch
Adam Witkowski
Wojciech Wojakowski
Jarosław Wójcik
Dariusz Dudek

References (26)
  1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
  2. Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. [Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society]. Kardiol Pol. 2014; 72(8): 761–765.
  3. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
  4. Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
  5. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
  6. Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
  7. Neumann F-J, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 34(10): 2949.
  8. Kereiakes D, Yeh R, Massaro J, et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
  9. Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
  10. Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
  11. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
  12. Stratmann G, deSilva A, Tseng E, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004: 1635–1639.
  13. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015; 373(11): 997–1009.
  14. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017; 377(12): 1132–1142.
  15. Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
  16. Mallifi JR, Lotfi AS. Management of STEMI in Patients on NOACs and Undergoing Primary PCI. Expert Analysis ACC website 2015.
  17. Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Inverventional Cardiology. .
  18. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
  19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
  20. Stone G, McLaurin B, Cox D, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216.
  21. Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
  22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
  23. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
  24. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
  25. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011; 14(1): 24–33.
  26. Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: